EUVIMEDOpdag EUVIMED
Open access

Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer

Lin Zhou iD, Jinchao Zhu iD, Yushan Liu, Bin Xu iD

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70162 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2026. Written by Lin Zhou and 3 co-authors. Institution: Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Major MEDLINE topics: Chemokine CXCL13, Urinary Bladder Neoplasms, Dendritic Cells, Lysosomal-Associated Membrane Protein 3. 27 references. The full text is freely available in PubMed Central. Funded by: Innovative Research Team of high-level local universities in Shanghai, Rising Stars of Medical Talent Youth Development Program.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

CXCL13 + T cells and LAMP3 + dendritic cells (DCs) are pivotal players in orchestrating anti‐tumor immune responses, particularly within tumor tertiary lymphoid structures (TLS). However, their heterogeneity, differentiation trajectories, and clinical relevance in bladder cancer remain incompletely defined. This study integrated single‐cell RNA sequencing (scRNA‐seq) data (16 bladder cancer patients, 113,905 post‐quality‐control cells) and spatial transcriptomics to characterize CXCL13 + T cell/LAMP3 + DC subsets, their differentiation pathways (via Velocyto trajectory analysis), and intercellular crosstalk (via receptor‐ligand mapping). A risk model (DTscore) was constructed using marker genes of these cells and validated in the IMvigor210 (atezolizumab‐treated bladder cancer) and TCGA‐BLCA cohorts. scRNA‐seq clustering identified 10 immune and 3 nonimmune cell types, with T cells stratified into 8 subpopulations (including CD4 + CXCL13 + T cells and CD8 + CXCL13 + T cells) and DCs into 9 subgroups (including LAMP3 + DCs). Receptor‐ligand mapping and spatial transcriptomics confirmed functional crosstalk between CXCL13 + T cells and LAMP3 + DCs via key pairs (e.g., CCR7‐CCL19, CXCR5‐CXCL13, PDCD1‐CD274) within TLS. The DTscore was developed using 8 marker genes (TSHZ2, ALOX5AP, GADD45G, TXN, CHN1, CCL19, CXCL13, ICA1) and exhibited robust prognostic and predictive performance: In the IMvigor210 cohort, high DTscore correlated with significantly poorer overall survival (OS) and a 3.27‐fold lower immunotherapy response rate (11% vs. 36%, p = 4.23e‐07); multivariate Cox regression confirmed DTscore as an independent OS predictor (hazard ratio = 1.97, p < 0.001). DTscore retained prognostic value in TCGA‐BLCA (OS: p = 0.003; disease‐specific survival: p < 0.001) and effectively predicted atezolizumab response even in the “immune desert” phenotype ( p = 0.04). Combining DTscore with tumor mutational burden/tumor neoantigen burden yielded an AUC of 0.8122 for response prediction. Additionally, high DTscore was associated with higher OS hazard ratios in patients with wild‐type TTN, RB1, EP300, or FGFR3 (all p < 0.01), while FGFR3 mutations correlated with lower immune checkpoint/CXCL13 expression. This study delineates the heterogeneity and interactions of CXCL13 + T cell/LAMP3 + DC subsets in bladder cancer TLS and validates DTscore as a robust tool for predicting OS and immunotherapy response, offering a potential guide for personalized bladder cancer treatment.

Subjects

MeSH terms (MEDLINE)

Chemokine CXCL13Urinary Bladder NeoplasmsDendritic CellsLysosomal-Associated Membrane Protein 3ImmunotherapyT-LymphocytesHumansPrognosisFemaleBiomarkers, TumorGene Expression Regulation, NeoplasticMaleNeoplasm Proteins

Substances

Chemokine CXCL13CXCL13 protein, humanLysosomal-Associated Membrane Protein 3LAMP3 protein, humanBiomarkers, TumorNeoplasm Proteins

Authors and institutions

  • Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID profiles: Lin Zhou, Jinchao Zhu, Bin Xu

Funding

  • Innovative Research Team of high-level local universities in Shanghai
  • Rising Stars of Medical Talent Youth Development Program

Cite

APA

Zhou, L., Zhu, J., Liu, Y., & Xu, B. (2026). Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70162

Vancouver

Zhou L, Zhu J, Liu Y, Xu B. Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70162

BibTeX
@article{Zhou2026,
  author = {Zhou, Lin and Zhu, Jinchao and Liu, Yushan and Xu, Bin},
  title = {Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70162}
}
Start for free →